Curie.Bio

Drug Discovery

Tesseract Medical Research is a biotechnology and medical sciences business focused on delivering nutrition to meet unmet needs.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Thrive Earlier Detection Corp. is a healthcare company focused on revolutionizing cancer diagnosis through its innovative blood testing platform. The company specializes in CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to detect various types of cancer at their earliest stages, even before symptoms arise. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate earlier cancer detection into routine medical care. The company's approach combines targeted DNA and protein analysis with real-world data and machine learning to provide comprehensive result interpretation and facilitate follow-up testing and oncology care. Thrive Earlier Detection Corp. operates as a subsidiary of Exact Sciences Corporation, reflecting its commitment to enhancing cancer detection and improving patient outcomes.

Astoria Biologica is developing novel therapies for multiple sclerosis

Decrypt Biomedicine is a biotechnology company focused on the development of small-molecule drugs that target cryptic binding sites on proteins. By identifying and leveraging these previously overlooked sites, the company aims to create innovative therapeutic solutions. Currently, Decrypt Biomedicine is operating in stealth mode, indicating a strategic approach to research and development while concealing its specific projects and advancements. The company's unique focus on cryptic binding sites positions it at the forefront of drug discovery, potentially leading to breakthroughs in treating various diseases.

Differentiated Therapeutics focuses on designing and developing transformative disease-modifying therapies aimed at addressing unmet medical needs. The company specializes in targeted protein degradation (TPD) therapies, utilizing advanced computational tools, including artificial intelligence and physics-based simulations, to discover, design, and optimize novel protein degraders. This innovative approach enables the development of targeted treatments for oncology indications, addressing the genetically defined drivers of diseases. By leveraging cutting-edge technology, Differentiated Therapeutics seeks to provide effective solutions for patients facing significant health challenges.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.